NCT02912247View on ClinicalTrials.gov

Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

September 22, 2017

Study Completion Date

September 22, 2017

Conditions
Healthy
Interventions
DRUG

human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection

human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once

DRUG

adalimumab

adalimumab, 40mg,subcutaneous injection,once

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT02912247 - Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers | Biotech Hunter | Biotech Hunter